Gilde Healthcare portfolio company Synox Therapeutics announces positive topline results from the Phase 3 TANGENT study
TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor Volume Score (TVS), and clinically meaningful improvements in PROMIS-PF...
13. April 2026